GKOS

GKOS

USD

Glaukos Corporation Common Stock

$85.495-0.365 (-0.425%)

实时价格

Healthcare
医疗设备
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$85.860

最高价

$88.290

最低价

$85.235

成交量

0.50M

公司基本面

市值

4.9B

所属行业

医疗设备

国家/地区

United States

交易统计

平均成交量

1.05M

交易所

NYQ

货币

USD

52周价格范围

最低价 $73.16当前价 $85.495最高价 $163.71

相关新闻

BusinessWire

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its

查看更多
Glaukos Announces Participation in Upcoming Investor Conferences
Analyst Upgrades

JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $120

JP Morgan analyst Allen Gong maintains Glaukos with a Overweight and raises the price target from $110 to $120.

查看更多
JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $120
Analyst Upgrades

Citigroup Maintains Buy on Glaukos, Raises Price Target to $113

Citigroup analyst Joanne Wuensch maintains Glaukos with a Buy and raises the price target from $110 to $113.

查看更多
Citigroup Maintains Buy on Glaukos, Raises Price Target to $113
Analyst Upgrades

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $122

Wells Fargo analyst Larry Biegelsen maintains Glaukos with a Overweight and raises the price target from $120 to $122.

查看更多
Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $122
Analyst Upgrades

Needham Maintains Buy on Glaukos, Raises Price Target to $117

Needham analyst David Saxon maintains Glaukos with a Buy and raises the price target from $115 to $117.

查看更多
Needham Maintains Buy on Glaukos, Raises Price Target to $117
Analyst Upgrades

BTIG Maintains Buy on Glaukos, Raises Price Target to $116

BTIG analyst Ryan Zimmerman maintains Glaukos with a Buy and raises the price target from $104 to $116.

BusinessWire

Glaukos Announces Third Quarter 2025 Financial Results

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial